New 'Living Drug' trial targets Tough-to-Treat cancers
NCT ID NCT07152236
Summary
This early-stage study is testing a new type of personalized cell therapy called B7H3 CAR-T in people with advanced solid tumors. Doctors will take a patient's own immune cells, modify them in a lab to better target their cancer, and then infuse them back. The main goals are to check if the treatment is safe and to see if it can shrink tumors in patients who have run out of standard options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan Taixin Hospital
RECRUITINGDongguan, Guangdong, 523125, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.